Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: A novel treatment method is required for recalcitrant common warts. Objective: This study aimed to compare the complete wart removal rate of cidofovir, a broad-spectrum antiviral agent, intralesional injection and sodium tetradecyl sulfate intralesional injection. Methods: This retrospective study included 45 patients with recalcitrant common warts on the hands and/or feet, treated with cidofovir or sodium tetradecyl sulfate intralesional injection. Results: The treatment results were evaluated in three groups as follows: (1) failure - recalcitrant common warts remaining despite three or more injections, (2) success - free from warts for more than 6 months after the injection, and (3) recurrence. The cidofovir group (n=22) showed significantly higher treatment success rates than the sodium tetradecyl sulfate group (n=23) (90.91% vs. 26.09%, p＜0.001). Two immunosuppressed patients in the cidofovir group had recurrent lesions after 2 months of being declared free from warts. Considering adverse effects, two patients in the cidofovir group complained of bulla formation with severe pain requiring narcotic painkillers. Conclusion: Although this study has the limitations of a small sample size and retrospective design, patients with recalcitrant common warts showed a dramatic response to the treatment with cidofovir intralesional injection, with minimal complications.
Abstract
Background: A novel treatment method is required for recalcitrant common warts. Objective: This study aimed to compare the complete wart removal rate of cidofovir, a broad-spectrum antiviral agent, intralesional injection and sodium tetradecyl sulfate intralesional injection. Methods: This retrospective study included 45 patients with recalcitrant common warts on the hands and/or feet, treated with cidofovir or sodium tetradecyl sulfate intralesional injection. Results: The treatment results were evaluated in three groups as follows: (1) failure - recalcitrant common warts remaining despite three or more injections, (2) success - free from warts for more than 6 months after the injection, and (3) recurrence. The cidofovir group (n=22) showed significantly higher treatment success rates than the sodium tetradecyl sulfate group (n=23) (90.91% vs. 26.09%, p＜0.001). Two immunosuppressed patients in the cidofovir group had recurrent lesions after 2 months of being declared free from warts. Considering adverse effects, two patients in the cidofovir group complained of bulla formation with severe pain requiring narcotic painkillers. Conclusion: Although this study has the limitations of a small sample size and retrospective design, patients with recalcitrant common warts showed a dramatic response to the treatment with cidofovir intralesional injection, with minimal complications.
참고문헌 (24)
- Massing AM, "Natural history of warts. A twoyear study", Arch Dermatol, 87, pp.306~310 (1963)
- Dicle O, "Choice of immunosuppressants and the risk of warts in renal transplant recipients", Acta Derm Venereol, 88, pp.294~295 (2008)
- Timmer MR, "Recalcitrant plantar warts during azathioprine therapy for Crohn's disease", Ann Gastroenterol, 26, pp.173~174 (2013)
- Leow MQH, "The impact of viral warts on the quality of life of patients", Dermatol Nurs, 15, pp.44~48 (2016)
- Broganelli P, "Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts", Dermatol Ther, 25, pp.468~471 (2012)
- Andrei G, "Induction of apoptosis by cidofovir in human papillomavirus(HPV)-positive cells", Oncol Res, 12, pp.397~408 (2000)
- Zabawski EJ Jr, "Topical and intralesional cidofovir : a review of pharmacology and therapeutic effects", J Am Acad Dermatol, 39(5 Pt 1), pp.741~745 (1998)
- Locke RK, "Controlled intralesional deposition of a sclerotic agent in verruca therapy", Int J Dermatol, 9, pp.278~282 (1970)
- Li X, "Clinical and dermoscopic features of common warts", J Eur Acad Dermatol Venereol, 31, pp.e308~e310 (2017)
- Kimura U, "Long-pulsed 1064-nm neodymium : yttrium-aluminum-garnet laser treatment for refractory warts on hands and feet", J Dermatol, 41, pp.252~257 (2014)
- Park HS, "Pulsed dye laser treatment for viral warts : a study of 120 patients", J Dermatol, 35, pp.491~498 (2008)
- Iwatsuki K, "Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction", Arch Dermatol, 122, pp.655~659 (1986)
- Sinha S, "Immunomodulators in warts:unexplored or ineffective?", Indian J Dermatol, 60, pp.118~129 (2015)
- Mun JH, "Oral zinc sulfate treatment for viral warts : an open-label study", J Dermatol, 38, pp.541~545 (2011)
- 최윤석, "Topical Immunotherapy with Diphenylcyclopropenone Is Effective and Preferred in the Treatment of Periungual Warts", Annals of Dermatology, 25(4), pp.434~439 (2013), 대한피부과학회
- Dawe S, "Treatment of recalcitrant viral warts with topical diphencyprone", J Am Acad Dermatol, 52(Suppl), pp.P134~ (2005)
- Shaheen MA, "Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR)vaccine in treatment of multiple warts: a comparative clinical and immunological study", Dermatol Ther, 28, pp.194~200 (2015)
- Stanley M, "Immune responses to human papillomavirus", Vaccine, 24(Suppl 1), pp.S16~S22 (2006)
- Cunningham DJ, "Needling versus liquid nitrogen cryotherapy for the treatment of pedal warts a randomized controlled pilot study", J Am Podiatr Med Assoc, 104, pp.394~401 (2014)
- Yang MY, "Quadrivalent human papilloma virus vaccine for the treatment of multiple warts : a retrospective analysis of 30 patients", J Dermatolog Treat, 30, pp.405~409 (2019)
- Nischal KC, "A novel modification of the autoimplantation therapy for the treatment of multiple, recurrent and palmoplantar warts", J Cutan Aesthet Surg, 5, pp.26~29 (2012)
- Androphy EJ, "Fitzpatrick’s dermatology in general medicine" (2012), McGraw-Hill
- Broekema FI, "Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis", Eur Arch Otorhinolaryngol, 265, pp.871~879 (2008)
- Mertens B, "Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms", Oncotarget, 7, pp.47302~47318 (2016)